Results 241 to 250 of about 100,218 (313)

Farnesoid X receptor prevents hyperuricemia via activating ATP‐binding cassette subfamily G member 2

Rheumatology &Autoimmunity, EarlyView.
Farnesoid X receptor (FXR) activation reduces serum uric acid levels by upregulating the intestinal urate transporter ATP‐binding cassette subfamily G member 2 (ABCG2). These findings uncover a novel metabolic pathway for urate excretion and suggest that FXR agonists (e.g., obeticholic acid), represent a promising therapeutic strategy for the treatment
Rui Li, Guo Tang, Ye Yu, Guang‐Liang Chen, Liangjing Lu, Juan Wang   +5 more
wiley   +1 more source

Advancing systemic therapy for biliary tract cancer: current strategies and emerging paradigms. [PDF]

Front Oncol
Choucair K, Chamseddine S, Azmi A, Philip PA.   +3 more
europepmc   +1 more source

Direct Choledochoscopic Visualization of Living <i>Clonorchis sinensis</i> in the Biliary Tract. [PDF]

Balkan Med J
Zhili M, Lei Y, Xiaohong Y, Ning F, Genshu W.   +4 more
europepmc   +1 more source

Propensity Score Analysis of Second-Line Chemotherapy Outcome in Advanced Biliary Tract Cancer. [PDF]

J Clin Med
Thanasombunsukh K, Charoentum C, Tantraworasin A, Khorana J.   +3 more
europepmc   +1 more source

Facility Type Predicts Completeness of Oncologic Resection and Survival in Biliary Tract Cancers. [PDF]

J Gastrointest Cancer
Lal T, Dong W, Abul-Khoudoud SO, Mahipal A, Ammori JB, Hoehn RS.   +5 more
europepmc   +1 more source

Differences in the Biliary Microbiome Between Biliary Tract Cancer and Benign Biliary Disease. [PDF]

Microorganisms
Lee HJ, Park SH, Han SY, Lee JH, Kim DU, Seo HI.   +5 more
europepmc   +1 more source